If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Cagrilintide + Semaglutide combination
Batch documentation
Ask sales for the CagriSema COA matched to the offered batch. Review the recorded tests, specifications, and results against your QA and destination-market requirements before quotation.
Overview
CagriSema is the fixed-combination presentation pairing the long-acting amylin analogue Cagrilintide with the GLP-1 receptor agonist Semaglutide, sitting in Phase 3 development inside Novo Nordisk's REDEFINE program for chronic weight management. It represents the next generation of GLP-1-anchored weight pharmacology: layering an amylin-axis mechanism (acting on the area postrema and across the calcitonin-receptor family) over the established GLP-1 receptor mechanism. Because the two signalling pathways are anatomically separate and pharmacologically distinct, the combined dose produces additive weight-reduction effects beyond what maximal-dose Semaglutide monotherapy delivers in dose-equivalent comparisons. The catalogue default ratio is 1:1 by mass of Cagrilintide to Semaglutide; non-standard ratios are available for research workflows characterising ratio-dependent biology. For compounding pharmacy buyers, Vialdyne releases CagriSema as a pre-blended co-lyophilised vial against a ≥99.0% main-peak HPLC specification per component. The batch is released against a documented in-vial ratio rather than total mass alone. Co-lyophilisation is the right method here, not solution-phase mixing inside the cleanroom: amylin-class peptides have a well-documented surface-aggregation sensitivity in dilute aqueous solution, and the co-lyophilised cake locks the ratio at the freeze-drying step before that aggregation window opens. The released-batch COA reports both component purities individually by HPLC with MS identity; the measured ratio inside the vial is available on request and listed on the COA when tested. Three fill strengths, 5, 10, and 20 mg total, cover bench-scale and compounding-pharmacy dispensing workflows.
Applications & buyer fit
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Ratio target, the analytical method to verify it, stability protocol, and packaging are defined in the OEM brief before the first commercial run.
Primary buyer fit: 503A / 503B compounding pharmacies and academic and contract research laboratories.
Specifications
Nasal spray listing · US inventory
CagriSema is also listed in this catalog as a nasal spray solution.

Batch COAs and test reports
Each picture is a low-resolution preview of a report's first page, with batch and report numbers covered. For the full, clear report, ask our sales team, naming the product and strength.
Batch COACagriSema 2.5 mg + 2.5 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COACagriSema 5 mg + 5 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COACagriSema 10 mg + 10 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Independent test fails? Full refund. How it works
Browse all COAs and reportsRegulatory note
Supplied as a combination product still under investigation via Novo Nordisk's REDEFINE program; as of this writing it holds no approval as a finished drug. The applicable batch COA records the actual items tested; component-level data and a verified ratio can be included when agreed before quotation.
Selected literature
Frequently asked questions
Amylin-class peptides, Cagrilintide included, have a documented sensitivity to surface-mediated aggregation when held in dilute aqueous solution, the same physical chemistry that drives native amylin to form fibrils in the pancreatic islet under disease conditions. Co-lyophilising Cagrilintide with Semaglutide produces a stable solid-state cake where the ratio is locked in at the freeze-drying step and surface-aggregation effects don't manifest until reconstitution at point of use. Solution-phase mixing of separately-purchased vials is operationally possible but produces variable ratios and progressive amylin-component degradation over time. The pre-blended product also collapses the documentation chain: a single COA certifies both component purities and the verified in-vial ratio, simplifying the receiving pharmacy's QA file.
Two distinct signalling axes converge on the same clinical endpoint. Cagrilintide binds at the amylin / calcitonin-receptor family in the area postrema, where it contributes to satiety signalling and gastric-emptying delay. Semaglutide binds at the GLP-1 receptor across the arcuate nucleus and peripheral tissue beds, where it contributes appetite suppression and insulinotropic effects. Because the two signalling cascades reinforce rather than compete, layering them produces additive weight-reduction effects beyond what either monotherapy reaches at its own ceiling dose. The clinical-program rationale, validated in the Phase 2 REDEFINE-2 readouts, is that the combination delivers larger weight-reduction signals than maximal-dose Semaglutide monotherapy.
Yes. CagriSema is listed as a nasal spray solution (10 mg), filled in 10 mL or 20 mL bottles, with an MOQ of 10 bottles per content and fill. It is dispatched within the United States from US inventory; send an inquiry for current availability.
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Related peptides
Long-acting amylin analog
Nasal spray listed
GLP-1 receptor agonist
Nasal spray listed
GIP / GLP-1 dual receptor agonist
Nasal spray listed